Benjamin Dubansky, Brooke Dubansky, Brandon Ballengée, and Christopher Just, in collaboration with Le Bleu Perdu Project, "Fresh Sea," from the series Né dans le peche (Born in Sin), 2024. Digitized image from a histology slide of American alligator osteoderm, stained with a modified version of Ramón y Cajal’s picroindigo-carmine and Kernechtrot Nuclear Fast Red. Courtesy of the artists, Le Bleu Perdu Project, Atelier de la Nature.

News

Strong Outlook for Obesity Drugs

January 14, 2026

“2026 is the year of obesity pills,” CNBC declares, explaining that pills may be more convenient and sometimes cheaper than the injectable versions of GLP-1 drugs now available. In Issues, Laura A. Schmidt and Luc L. Hagenaars suggest that expanded use of this new class of drugs could hasten changes in government policies and food industry practices aimed at curbing obesity. Widespread use of the drugs could lead companies to formulate healthier products, for example, while also encouraging adoption of regulations, warning labels, and taxes to lower sales and consumption of ultra-processed commercial food products widely linked to obesity.

Posted by Tom Burroughs

Related Article

The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems

Laura A. Schmidt, Luc L. Hagenaars

A new class of medications that people are taking to control their weight could help redirect blame for obesity toward the broader food system and ineffective food policies.

Read More

Spring 2025: The Strange New Politics of Science

Read More